News Releases - Office of Public and Intergovernmental Affairs
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.
Menu
Menu
Veterans Crisis Line Badge

Office of Public and Intergovernmental Affairs

 

VA announces new clinical trial for Veterans with COVID-19

Aug. 28, 2020, 12:01:00 PM

Printable Version


 

VA announces new clinical trial for Veterans with COVID-19

Researchers to study blood plasma for treating seriously ill patients

 

WASHINGTON  The Department of Veterans Affairs (VA) today announced a new clinical trial to study convalescent plasma for treating seriously ill COVID-19 patients as part of a larger effort to give Veterans faster access to potential COVID-19 treatments and test the treatments’ effectiveness.

The trial is the first of multiple studies in VA Coronavirus Research and Efficacy Studies (VA CURES), a master protocol that offers a standardized framework for studying potential treatments for COVID-19 without the need for a new study design and protocol each time.

“This trial will go a long way toward helping in the fight against COVID-19,” said VA Secretary Robert Wilkie. “VA CURES will provide valuable information that will benefit our Veterans who are battling COVID-19, as well as other patients and the medical community in general.”

The trial will enroll around 700 Veterans with COVID-19 who are hospitalized at VA medical centers. A study team will randomize the study volunteers to receive either convalescent plasma or a saline placebo, and track and assess recovery and effects of the treatment.

Convalescent plasma is donated by people who have recovered from COVID-19 and have antibodies against the virus in their blood. Antibodies are proteins the body makes to fight infections.

The U.S. Food and Drug Administration (FDA) previously authorized the use of convalescent plasma as an investigational treatment for COVID-19 through FDA’s expanded access program. The program, used widely throughout the nation, including at many VA sites, ended Aug. 28. FDA has since authorized the emergency use of the therapy based on the available scientific evidence to date. FDA stresses further evidence from rigorous trials — such as the new VA study — is “critically important” for establishing safety and efficacy.

Visit VA COVID-19 research for more information.

###



Disclaimer of Hyperlinks

The appearance of external hyperlinks does not constitute endorsement by the Department of Veterans Affairs of the linked web sites, or the information, products or services contained therein. For other than authorized VA activities, the Department does not exercise any editorial control over the information you may find at these locations. All links are provided with the intent of meeting the mission of the Department and the VA website. Please let us know about existing external links which you believe are inappropriate and about specific additional external links which you believe ought to be included by emailing newmedia@va.gov.



People wishing to receive e-mail from VA with the latest news releases and updated fact sheets can subscribe to the
VA Office of Public Affairs Distribution List.

Back to News Releases Index



Search VA News Releases

(mm/dd/yyyy)
(mm/dd/yyyy)